Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal

Stock News

Yesterday

Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent LYN/BTK dual-target inhibitor birelentinib as a monotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL), have been officially published in the international authoritative hematology journal Blood Cancer Journal, which boasts an impact factor of 13.8.

Birelentinib is a globally pioneering LYN/BTK dual-target inhibitor designed to achieve broad-spectrum coverage across different DLBCL subtypes by simultaneously blocking both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways. The TAI-SHAN9 study enrolled patients who had previously received one to five lines of systemic therapy.

The study findings reveal that birelentinib monotherapy at both 50mg and 75mg doses demonstrated broad-spectrum antitumor activity across various molecular subtypes, accompanied by a manageable safety profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/1144997108"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144997108\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144997108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144997108","market":"hk","top_or_hot":-1,"title":"Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal","media":"Stock News","content":"<p><b>Dizal Pharmaceutical Co., Ltd.</b> (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent LYN/BTK dual-target inhibitor birelentinib as a monotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL), have been officially published in the international authoritative hematology journal <b>Blood Cancer Journal</b>, which boasts an impact factor of 13.8.<br><br>Birelentinib is a globally pioneering LYN/BTK dual-target inhibitor designed to achieve broad-spectrum coverage across different DLBCL subtypes by simultaneously blocking both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways. The TAI-SHAN9 study enrolled patients who had previously received one to five lines of systemic therapy.<br><br>The study findings reveal that birelentinib monotherapy at both 50mg and 75mg doses demonstrated broad-spectrum antitumor activity across various molecular subtypes, accompanied by a manageable safety profile.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-09 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Dizal Pharmaceutical Co., Ltd.</b> (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent LYN/BTK dual-target inhibitor birelentinib as a monotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL), have been officially published in the international authoritative hematology journal <b>Blood Cancer Journal</b>, which boasts an impact factor of 13.8.<br><br>Birelentinib is a globally pioneering LYN/BTK dual-target inhibitor designed to achieve broad-spectrum coverage across different DLBCL subtypes by simultaneously blocking both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways. The TAI-SHAN9 study enrolled patients who had previously received one to five lines of systemic therapy.<br><br>The study findings reveal that birelentinib monotherapy at both 50mg and 75mg doses demonstrated broad-spectrum antitumor activity across various molecular subtypes, accompanied by a manageable safety profile.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688192","symbol_name":"迪哲医药-U","start_time":0,"source_url":"","article_id":"1144997108","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144997108","pubTimestamp":1788940815,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","BK1515":"抗疫概念","BK1161":"生物科技","BK0239":"医药制造","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"Dizal Pharmaceutical 的 Birelentinib 在《血癌杂志》上发表的淋巴瘤研究中显示出前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"09939":1},"content_text":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent LYN/BTK dual-target inhibitor birelentinib as a monotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL), have been officially published in the international authoritative hematology journal Blood Cancer Journal, which boasts an impact factor of 13.8.Birelentinib is a globally pioneering LYN/BTK dual-target inhibitor designed to achieve broad-spectrum coverage across different DLBCL subtypes by simultaneously blocking both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways. The TAI-SHAN9 study enrolled patients who had previously received one to five lines of systemic therapy.The study findings reveal that birelentinib monotherapy at both 50mg and 75mg doses demonstrated broad-spectrum antitumor activity across various molecular subtypes, accompanied by a manageable safety profile.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}